Vimian Group AB (publ)
VIMIAN
Rank in Stocks
#5435
Vimian Group AB (publ) operates as a global enterprise in the animal health... Vimian Group AB (publ) operates as a global enterprise in the animal health sector, segmenting its business into Specialty Pharma, MedTech, Diagnostics, and Veterinary Services. Through its Nextmune brand, the company delivers a comprehensive portfolio of proprietary diagnostic tools and both prescription and non-prescription therapies designed for the preventive care and ongoing management of chronic conditions in companion animals. The Indical Bioscience division provides specialized molecular and immunodiagnostic solutions, predominantly employed by laboratories for veterinary-specific applications across both livestock and companion animal health markets. Additionally, the VetFamily brand runs a membership-based platform that furnishes veterinary clinics with crucial procurement services, technology-enabled operational support (including online marketing, education, and human resources), and fosters a professional community. Finally, Movora is responsible for supplying orthopedic implants to veterinarians and academic institutions. Founded in 2020, Vimian Group's headquarters are located in Stockholm, Sweden.
Share Price
$4.23
Last synced: 2026-11-13
Market Cap
$2.25B
Change (1 day)
-0.20%
Change (1 year)
38.24%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Vimian Group AB (publ) (VIMIAN)
Category
Healthcare
Earnings for Vimian Group AB (publ) (VIMIAN)
Earnings in Sep 2026 TTM: $61.49M
According to Vimian Group AB (publ)'s latest financial reports, its current earnings (TTM) are $61.49M. In 2025 the company earned $54.86M, an increase over its 2024 earnings of $30.07M. The earnings shown on this page are earnings before interest and taxes, or EBIT.
Earnings history for Vimian Group AB (publ) from 2018 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $61.49M | 12.09% |
| 2025 | $54.86M | 82.44% |
| 2024 | $30.07M | 39.88% |
| 2023 | $21.50M | 2,069.10% |
| 2022 | $991.15K | -93.17% |
| 2021 | $14.51M | -80.05% |
| 2020 | $72.71M | -6,162.43% |
| 2019 | $-1.20M | 7.05% |
| 2018 | $-1.12M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $7.87B | 12,696.20% |
US
|
|
| $4.82B | 7,734.81% |
US
|
|
| $4.93B | 7,923.48% |
CN
|
|
| $1.48B | 2,305.04% |
US
|
|
| $1.66B | 2,596.16% |
US
|
Questions about Vimian Group AB (publ)'s net income
What is Vimian Group AB (publ)'s net income?
Vimian Group AB (publ)'s net income over the last twelve months is $61.49M, as of Sep 2026.
What was Vimian Group AB (publ)'s net income in 2025?
In 2025, Vimian Group AB (publ)'s net income was $54.86M, 82.44% more than in 2024 ($30.07M).
How has Vimian Group AB (publ)'s net income changed since 2020?
From 2020 to 2025, Vimian Group AB (publ)'s net income went from $72.71M to $54.86M, an average decline of 5.48% a year.
How does Vimian Group AB (publ)'s net income compare with similar companies?
Vimian Group AB (publ)'s net income ($61.49M) is lower than that of all 5 similar companies listed above. The highest among them is Thermo Fisher Scientific Inc., with $7.87B.